Aspira Pathlab & Diagnostics Share Price

30.95

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)
Detailed Quote

Corporate Action

Period From
Period To
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 07-Jun-2020 - -
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/06/2020 ,inter alia, to consider and approve We wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Saturday, June 13, 2020 to consider and approve the audited financial Statements of the Company for the quarter and year ended March 31, 2020. We further wish to inform you that in terms of the Companys Code of Conduct for Prevention of Insider Trading, the trading window for dealing in securities of the Company has been closed with effect from April 01, 2020 and shall re-open 48 hours after the financial results are made public. We request you to take the same on your records. Thanking you, This is to inform you that the Board of Directors of the Company, at their meeting held today at 3 p.m. has: 1. Approved the Audited financial results of the Company for the quarter and year ended 31st March, 2020. 2. Approved the appointment of S K Pandey, Company Secretary in Practice as Secretarial Auditor of the Company u/s 204 of the Companies Act, 2013 for the financial Year 2020-21. 3. Approved the appointment of Vishal J Bhanushali and Associates, Chartered Accountants as Internal Auditor of the Company for the financial year 2020-21. Pursuant to Regulation 30 of the Listing (Obligations & Disclosure Requirements) Regulations, 2015, this is to inform that, the Board of Directors in its meeting held on June 13, 2020 (on the recommendation of the Nomination and Remuneration Committee), approved the re-designation of Dr. Pankaj Shah from Managing Director to Managing Director(MD) and Chief Executive officer(CEO) of the Company. (As Per BSE Announcement dated on 13.06.2020)
Board Meeting - 27-Jan-2020 - -
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2020 ,inter alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31, 2019. Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed Public Notice published in the Newspapers viz.- Business Standard (in English) and Mumbai Lakshdeep (in Marathi), informing about the Board Meeting scheduled to be held on 4th February, 2020 to, inter alia, consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine months ended 31st December, 2019. (As Per BSE Announcement Dated 29.01.2020) Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III to the listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today has approved the unaudited Financial Results for third quarter and nine months ended December 31, 2019. The above financial Results along with the Limited Review Report on the Financial Results are enclosed herewith. The meeting of the Board of Directors was concluded at 5.15 p.m. Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III to the listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today has approved the unaudited Financial Results for third quarter and nine months ended December 31, 2019. The above financial Results along with the Limited Review Report on the Financial Results are enclosed herewith. The meeting of the Board of Directors was concluded at 5.15 p.m. Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III to the listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today has approved the unaudited Financial Results for third quarter and nine months ended December 31, 2019. The above financial Results along with the Limited Review Report on the Financial Results are enclosed herewith. The meeting of the Board of Directors was concluded at 5.30 p.m. (As Per BSE Announcement Dated 04.02.2020)
Board Meeting - 06-Nov-2019 - -
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III to the listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today has considered and approved the appointment of Mr. Ravindra R. Desai, as Chief Executive Officer of the Company. Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III to the listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today has considered and approved the appointment of Mr. Ravindra R. Desai, as Chief Executive Officer of the Company. (As Per BSE Announcement Dated 06.11.2019)
Board Meeting - 26-Oct-2019 - -
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2019 ,inter alia, to consider and approve We wish to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors of the Company is scheduled to be held on Saturday, November 02, 2019 to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2019. We request you to take the same on your records. Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III to the listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today has approved the unaudited Financial Results for the second quarter and half year ended September 30, 2019. (As Per BSE Announcement Dated on 02.11.2019)
Board Meeting - 17-Aug-2019 - -
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/08/2019 ,inter alia, to consider and approve We wish to inform that pursuant to Regulation 29(l)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the board of directors of the Company is scheduled to be held on August 21, 2019 to inter alia discuss and consider issuance and allotment of equity shares by way of preferential allotment, subject to obtaining the approval of the shareholders of the Company in the annual general meeting proposed to be convened. As per the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Companys Code of Conduct for Prevention of Insider Trading as adopted by the Company, the Trading Window for dealing in the securities of the Company will be closed for Designated Persons of the Company from August 01, 2019 till 48 hours after the conclusion of Board Meeting scheduled to be held on August 21, 2019 inter alia discuss and consider issuance and allotment of equity shares by way of preferential allotment. Kindly take the same on record. In relation to the proposed fund raising by preferential allotment of equity shares by the Aspira Pathlab & Diagnostics Limited (the Company). In furtherance to our letter dated July 31, 2019, with respect to the issuance of Equity Shares on a preferential basis, we wish to inform you that the board of directors of the Company (the Board) at its meeting held on August 21, 2019, subject to the approval of the shareholders of the Company, has approved the issue and allotment of up to 38,00,000 (Thirty Eight Lakhs) Equity Shares of face value of INR 10/- each, at an issue price Rs. 26 (Rupees Twenty Six) including premium of Rs. 16 (Rupees Sixteen) to strategic investors not forming part of promoter or promoter group, on a preferential basis, on terms and conditions as approved by the Board. We would also like to inform that an Annual General Meeting of the Members of the Company will be held on 21th September, 2019 for seeking their approval for the above issue of shares. (As Per BSE Announcement Dated On 21/08/2019)
Board Meeting - 31-Jul-2019 - -
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2019 ,inter alia, to consider and approve issuance and allotment of equity shares by way of preferential allotment, subject to obtaining the approval of the shareholders of the Company in the annual general meeting proposed to be convened. As per the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Companys Code of Conduct for Prevention of Insider Trading as adopted by the Company, the Trading Window for dealing in the securities of the Company will be closed for Designated Persons of the Company from August 01, 2019 till 48 hours after the conclusion of Board Meeting scheduled to be held on August 14, 2019 inter alia discuss and consider issuance and allotment of equity shares by way of preferential allotment. Preferential Issue of shares(Cancelled) (Cancelled) Inter alia, to consider and approve issuance and allotment of equity shares by way of preferential allotment, subject to obtaining the approval of the shareholders of the Company in the annual general meeting proposed to be convened (As per BSE Bulletin dated on 14/08/2019) The Board Meeting to be held on 14/08/2019 Stands Cancelled. (As Per BSE Announcement Dated 14.08.2019)
Board Meeting - 13-Jul-2019 - -
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2019 ,inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2019. This is to inform you that the Board of Directors of the Company, at their meeting held today at 3 p.m. has: 1. Approved the unaudited financial results of the Company for the quarter ended 30th June, 2019. 2. Recommended the Re- appointment of M/s P Khetan & Co., Chartered Accountants as the Statutory Auditor of the Company for the period of five consecutive years from the conclusion of the forthcoming Annual General Meeting, subject to approval of shareholders. 3. Approved re-appointment of Ms. Vandana Bhansali as Non-Executive Independent Directors of the Company for a second consecutive term of 5 years from 26th September, 2019. The meeting of the Board of Directors was concluded at 5.30 p.m. This is to inform you that the Board of Directors of the Company, at their meeting held today at 3 p.m. has Approved the un-audited financial results of the Company for the quarter ended June 30, 2019. The above financial Results along with the Limited Review Report on the Financial Results are enclosed herewith. The meeting of the Board of Directors was concluded at 5.30 p.m. In compliance with Regulation 30 of the SEBI (Listing Regulations and Disclosure Requirements) Regulations read with Para A of Part A of Schedule III to the said Regulations, we wish to inform you that the Audit Committee and the Board of Directors of the Company had at their respective meetings held today i.e. July 20, 2019, subject to approval of shareholders at the forthcoming Annual General Meeting( AGM), recommended the Re- appointment of M/s P Khetan & Co., Chartered Accountants (Firm Registartion No. 327386E) as the Statutory Auditors of the Company for the period of five consecutive years from the conclusion of the forthcoming Annual General Meeting, subject to approval of shareholders. (As Per BSE Announcement Dated On 20/07/2019)